Risk of Urolithiasis in Anorexia Nervosa: A Population-Based Cohort Study Using the Health Improvement Network

2017 ◽  
Vol 25 (5) ◽  
pp. 406-410 ◽  
Author(s):  
Michelle R. Denburg ◽  
Mary B. Leonard ◽  
Thomas O. Jemielita ◽  
Neville H. Golden ◽  
Gregory Tasian ◽  
...  
Keyword(s):  
Anorexia Nervosa ◽  
Cohort Study ◽  
Population Based ◽  
Health Improvement ◽  
The Health Improvement Network

scholarly journals Incidence and risk of celiac disease after type 1 diabetes: A population‐based cohort study using the health improvement network database

2018 ◽  
Vol 19 (8) ◽  
pp. 1422-1428 ◽  
Author(s):  
Mary Ellen Vajravelu ◽  
Ron Keren ◽  
David R. Weber ◽  
Ritu Verma ◽  
Diva D. De León ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cohort Study ◽  
Celiac Disease ◽  
Population Based ◽  
Health Improvement ◽  
Network Database ◽  
The Health Improvement Network

scholarly journals Risk of Fracture in Urolithiasis: A Population-Based Cohort Study Using the Health Improvement Network

2014 ◽  
Vol 9 (12) ◽  
pp. 2133-2140 ◽  
Author(s):  
Michelle R. Denburg ◽  
Mary B. Leonard ◽  
Kevin Haynes ◽  
Shamir Tuchman ◽  
Gregory Tasian ◽  
...  
Keyword(s):  
Cohort Study ◽  
Population Based ◽  
Health Improvement ◽  
Risk Of Fracture ◽  
The Health Improvement Network

Incidence and Risk of Celiac Disease in Individuals with Type 1 Diabetes over the Lifespan—A Population-Based Cohort Study Using the Health Improvement Network Database

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1498-P
Author(s):  
MARY ELLEN VAJRAVELU ◽  
DIVA DE LEON ◽  
DAVID R. WEBER ◽  
RON KEREN ◽  
MICHELLE R. DENBURG ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cohort Study ◽  
Celiac Disease ◽  
Population Based ◽  
Health Improvement ◽  
Network Database ◽  
The Health Improvement Network

scholarly journals All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database

2017 ◽  
Vol 102 (5) ◽  
pp. 1719-1725 ◽  
Author(s):  
Konstantinos A. Toulis ◽  
Brian H. Willis ◽  
Tom Marshall ◽  
Balachadran Kumarendran ◽  
Krishna Gokhale ◽  
...  
Keyword(s):  
Cohort Study ◽  
Population Based ◽  
Low Risk ◽  
Health Improvement ◽  
Total Study Population ◽  
Risk Of Death ◽  
Network Database ◽  
All Cause Mortality ◽  
Risk Patients ◽  
The Health Improvement Network

Abstract Context: Empagliflozin was found to decrease mortality in patients with type 2 diabetes mellitus (T2DM) and a prior cardiovascular disease (CVD) event. Objectives: To establish whether these benefits can be replicated in a real-world setting, should be expected with the use of dapagliflozin, and apply to T2DM patients at low risk of CVD. Design: General practice, population-based, retrospective cohort study (January 2013 to September 2015). Setting: The Health Improvement Network database. Participants: A total of 22,124 T2DM patients (4444 exposed to dapagliflozin; 17,680 unexposed T2DM patients) matched for age, sex, body mass index, T2DM duration, and smoking. Main Outcome Measures: The primary outcome was all-cause mortality (high and low risk for CVD) in the total study population, expressed as the adjusted incidence rate ratio (aIRR) with 95% confidence intervals (CIs). As a secondary analysis in the low-risk population, all-cause mortality and incident CVD were considered. Results: Patients with T2DM exposed to dapagliflozin were significantly less likely to die of any cause (aIRR: 0.50; 95% CI: 0.33 to 0.75; P = 0.001). Similarly, in low-risk patients, death from any cause was significantly lower in the cohort exposed to dapagliflozin (aIRR: 0.44; 95% CI: 0.25 to 0.78; P = 0.002). The difference in the risk of incident CVD did not reach statistical significance between groups in low-risk patients (aIRR: 0.89; 95% CI: 0.61 to 1.31; P = 0.546). Conclusions: Patients with T2DM who were exposed to dapagliflozin had a lower risk of death from any cause irrespective of baseline CVD status.

Sign in / Sign up

Export Citation Format

Share Document